Table 14.
Occurrence of resistance to selected antimicrobials in different Salmonella Typhimurium and monophasic S. Typhimurium from carcases of fattening pigs in 2015
| Country | Ampicillin | Azithromycin | Cefotaxime | Ceftazidime | Chloramphenicol | Ciprofloxacin | Colistina | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
| Salmonella Typhimurium | ||||||||||||||
| Belgium | 40 | 75 | 40 | 0 | 40 | 2.5 | 40 | 2.5 | 40 | 10 | 40 | 0 | 40 | 0 |
| Croatia | 7 | 71.4 | 7 | 0 | 7 | 0 | 7 | 0 | 7 | 28.6 | 7 | 0 | 7 | 0 |
| Czech Republic | 3 | 66.7 | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 33.3 | 3 | 0 | 3 | 0 |
| Denmark | 12 | 50 | 12 | 8.3 | 12 | 0 | 12 | 0 | 12 | 16.7 | 12 | 0 | 12 | 0 |
| Estonia | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| France | 34 | 44.1 | 34 | 0 | 34 | 0 | 34 | 0 | 34 | 29.4 | 34 | 2.9 | 34 | 0 |
| Hungary | 2 | 50 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 50 | 2 | 0 | 2 | 0 |
| Poland | 5 | 60 | 5 | 0 | 5 | 0 | 5 | 0 | 5 | 40 | 5 | 60 | 5 | 0 |
| Romania | 7 | 85.7 | 7 | 0 | 7 | 0 | 7 | 0 | 7 | 14.3 | 7 | 0 | 7 | 0 |
| Spain | 22 | 100 | 22 | 0 | 22 | 4.5 | 22 | 0 | 22 | 59.1 | 22 | 27.3 | 22 | 0 |
| United Kingdom | 2 | 100 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 50 | 2 | 0 | 2 | 0 |
| Total (11 MSs) | 135 | 68.1 | 135 | 0.7 | 135 | 1.5 | 135 | 0.7 | 135 | 27.4 | 135 | 7.4 | 135 | 0 |
| Monophasic Salmonella Typhimurium | ||||||||||||||
| Belgium | 31 | 87.1 | 31 | 3.2 | 31 | 0 | 31 | 0 | 31 | 9.7 | 31 | 0 | 31 | 0 |
| Croatia | 6 | 83.3 | 6 | 0 | 6 | 0 | 6 | 0 | 6 | 16.7 | 6 | 0 | 6 | 0 |
| Cyprus | 2 | 100 | 2 | 50.0 | 2 | 0 | 2 | 0 | 2 | 50 | 2 | 0 | 2 | 0 |
| Czech Republic | 2 | 50 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 |
| Denmark | 24 | 83.3 | 24 | 0 | 24 | 0 | 24 | 0 | 24 | 4.2 | 24 | 0 | 24 | 0 |
| Estonia | 1 | 100 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| France | 32 | 90.6 | 32 | 0 | 32 | 0 | 32 | 0 | 32 | 15.6 | 32 | 0 | 32 | 6.3 |
| Germany | 28 | 75 | 28 | 0 | 28 | 0 | 28 | 0 | 28 | 21.4 | 28 | 3.6 | 28 | 0 |
| Hungary | 3 | 100 | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 0 |
| Malta | 4 | 75 | 4 | 0 | 4 | 0 | 4 | 0 | 4 | 25 | 4 | 0 | 4 | 0 |
| Portugal | 13 | 100 | 13 | 0 | 13 | 0 | 13 | 0 | 13 | 7.7 | 13 | 30.8 | 13 | 15.4 |
| Slovakia | 2 | 100 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 |
| Spain | 39 | 89.7 | 39 | 0 | 39 | 0 | 39 | 0 | 39 | 12.8 | 39 | 7.7 | 39 | 0 |
| Total (13 MSs) | 187 | 86.6 | 187 | 1.1 | 187 | 0 | 187 | 0 | 187 | 12.8 | 187 | 4.3 | 187 | 2.1 |
| Iceland | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Country | Gentamicin | Nalidixic acid | Sulfamethoxazole | Tetracycline | Tigecyclineb | Trimethoprim | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
| Salmonella Typhimurium | ||||||||||||
| Belgium | 40 | 0 | 40 | 0 | 40 | 47.5 | 40 | 42.5 | 40 | 0 | 40 | 25.0 |
| Croatia | 7 | 0 | 7 | 0 | 7 | 57.1 | 7 | 71.4 | 7 | 0 | 7 | 42.9 |
| Czech Republic | 3 | 0 | 3 | 0 | 3 | 66.7 | 3 | 66.7 | 3 | 0 | 3 | 0 |
| Denmark | 12 | 0 | 12 | 0 | 12 | 50.0 | 12 | 41.7 | 12 | 0 | 12 | 33.3 |
| Estonia | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| France | 34 | 0 | 34 | 2.9 | 34 | 58.8 | 34 | 50 | 34 | 0 | 34 | 8.8 |
| Hungary | 2 | 0 | 2 | 0 | 2 | 50.0 | 2 | 50 | 2 | 0 | 2 | 0 |
| Poland | 5 | 0 | 5 | 40.0 | 5 | 60.0 | 5 | 60 | 5 | 0 | 5 | 0 |
| Romania | 7 | 14.3 | 7 | 0 | 7 | 28.6 | 7 | 42.9 | 7 | 0 | 7 | 28.6 |
| Spain | 22 | 0 | 22 | 27.3 | 22 | 90.9 | 22 | 100 | 22 | 4.5 | 22 | 0 |
| United Kingdom | 2 | 50.0 | 2 | 0 | 2 | 100 | 2 | 50 | 2 | 0 | 2 | 50.0 |
| Total (11 MSs) | 135 | 1.5 | 135 | 6.7 | 135 | 58.5 | 135 | 56.3 | 135 | 0.7 | 135 | 17 |
| Monophasic Salmonella Typhimurium | ||||||||||||
| Belgium | 31 | 3.2 | 31 | 0 | 31 | 87.1 | 31 | 80.6 | 31 | 3.2 | 31 | 16.1 |
| Croatia | 6 | 0 | 6 | 0 | 6 | 83.3 | 6 | 83.3 | 6 | 0 | 6 | 16.7 |
| Cyprus | 2 | 100 | 2 | 0 | 2 | 100 | 2 | 100 | 2 | 0 | 2 | 50.0 |
| Czech Republic | 2 | 0 | 2 | 0 | 2 | 50.0 | 2 | 50.0 | 2 | 0 | 2 | 0 |
| Denmark | 24 | 0 | 24 | 0 | 24 | 83.3 | 24 | 54.2 | 24 | 0 | 24 | 8.3 |
| Estonia | 1 | 0 | 1 | 0 | 1 | 100 | 1 | 100 | 1 | 0 | 1 | 0 |
| France | 32 | 6.3 | 32 | 0 | 32 | 87.5 | 32 | 96.9 | 32 | 0 | 32 | 9.4 |
| Germany | 28 | 7.1 | 28 | 0 | 28 | 85.7 | 28 | 78.6 | 28 | 0 | 28 | 21.4 |
| Hungary | 3 | 0 | 3 | 0 | 3 | 100 | 3 | 100 | 3 | 0 | 3 | 0 |
| Malta | 4 | 0 | 4 | 0 | 4 | 100 | 4 | 100 | 4 | 0 | 4 | 0 |
| Portugal | 13 | 0 | 13 | 15.4 | 13 | 100 | 13 | 100 | 13 | 7.7 | 13 | 30.8 |
| Slovakia | 2 | 0 | 2 | 0 | 2 | 100 | 2 | 100 | 2 | 0 | 2 | 0 |
| Spain | 39 | 2.6 | 39 | 5.1 | 39 | 79.5 | 39 | 92.3 | 39 | 0 | 39 | 12.8 |
| Total (13 MSs) | 187 | 4.3 | 187 | 2.1 | 187 | 86.1 | 187 | 84.5 | 187 | 1.1 | 187 | 14.4 |
| Iceland | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
All Salmonella isolates tested were susceptible to meropenem. N: number of isolates tested; % Res: percentage of microbiologically resistant isolates.
a
A number of colistin‐resistant isolates are undergoing testing for the presence of the mcr‐1 gene. The reported occurrence of colistin resistance does not equate to the occurrence of mcr‐1. ECOFF applied 2 mg/L.
b
ECOFF applied 1 mg/L.